advertisement
Abstract #46873 Published in IGR 13-3
Safety profile of latanoprost versus timolol in patients with open angle glaucoma or ocular hypertension: Post 2000 setting
Gupta J; Siddiqui MK; Jindal R; Sehgal MValue in Health 2011; 14: 54
OBJECTIVES: To systematically compare the safety of latanoprost versus timolol through meta-analysis of randomized controlled trials (RCTs) in open angle glaucoma (OAG) or ocular hypertension (OH). METHODS: Medline and Cochrane Central Register of Controlled Trials (CCTR) were searched for RCTs published post 2000, assessing head to head comparison of latanoprost vs. timolol in OAG or OH. Studies were assessed for inclusion/exclusion based on a prespecified protocol. Two reviewers undertook data extraction independently. Any disagreement was resolved by a third reviewer. A customized spreadsheet was used to extract the relevant outcomes, including the study duration, sample size, number of patients with local and systemic side effects and the proportion of withdrawals due to adverse events. RESULTS: Four RCTs enrolling 1688 patients met the inclusion criteria out of the 289 studies identified. Latanoprost was associated with an increased incidence of hyperemia (risk ratio (RR) = 2.7, 95% CI = 1.37 to 5.28), iris pigmentation (RR = 10.81, 95% CI = 1.37 to 85.47) and pruritus (RR = 3.05, 95% CI = 1.06to8.73)comparedtotimolol(LevelIevidence). Also, oneRCT(LevelIIevidence) reported that latanoprost was associated with increased incidences of eyelash changes (risk difference (RD) = 0.23, 95% CI = 0.16 to 0.29; number needed to harm (NNH) = 4, 95% CI = 3 to 6). Other AEs commonly observed with both the treatments were blepharitis, cataract, dry eye, eye irritation, eye pain and keratitis. There was no statistically significant difference for withdrawals due to AEs across both the treatments (RD = 0.02, 95% CI = -0.02 to 0.05). CONCLUSIONS: Timolol displayed a better safety profile than latanoprost for adverse events including hyperemia, iris pigmentationandpruritus. However, longtermsafetycouldnotbeassessedasfew included studies evaluated patients beyond six months.
J. Gupta. Heron Health Private Ltd, Chandigarh, Chandigarh, India.
Classification:
11.4 Prostaglandins (Part of: 11 Medical treatment)
11.3.4 Betablocker (Part of: 11 Medical treatment > 11.3 Adrenergic drugs)
